Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
$4.21
-3.8%
$4.28
$1.32
$7.75
$220.29M0.08175,614 shs102,819 shs
Codexis, Inc. stock logo
CDXS
Codexis
$2.33
+3.1%
$2.55
$0.96
$3.87
$211.80M2.481.65 million shs792,841 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$12.70
-0.3%
$9.14
$1.35
$15.02
$213.95M0.27492,610 shs129,572 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$4.25
+1.5%
$4.44
$3.62
$16.25
$50.51M1.34100,236 shs21,103 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
-1.58%+0.23%-0.46%-0.61%+196.27%
Codexis, Inc. stock logo
CDXS
Codexis
-3.00%-5.44%-18.41%+29.89%-7.38%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-9.90%+7.24%+15.29%+108.51%+755.03%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
+1.45%-4.34%-8.52%-3.01%-9.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
$4.21
-3.8%
$4.28
$1.32
$7.75
$220.29M0.08175,614 shs102,819 shs
Codexis, Inc. stock logo
CDXS
Codexis
$2.33
+3.1%
$2.55
$0.96
$3.87
$211.80M2.481.65 million shs792,841 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$12.70
-0.3%
$9.14
$1.35
$15.02
$213.95M0.27492,610 shs129,572 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$4.25
+1.5%
$4.44
$3.62
$16.25
$50.51M1.34100,236 shs21,103 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
-1.58%+0.23%-0.46%-0.61%+196.27%
Codexis, Inc. stock logo
CDXS
Codexis
-3.00%-5.44%-18.41%+29.89%-7.38%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-9.90%+7.24%+15.29%+108.51%+755.03%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
+1.45%-4.34%-8.52%-3.01%-9.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
2.75
Moderate Buy$8.3698.74% Upside
Codexis, Inc. stock logo
CDXS
Codexis
2.00
Hold$5.00114.59% Upside
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.60
Moderate Buy$13.506.30% Upside
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
2.33
Hold$11.00158.76% Upside

Current Analyst Ratings Breakdown

Latest RADX, CDXS, CAMP, and QTTB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2026
Codexis, Inc. stock logo
CDXS
Codexis
Reiterated RatingOverweight
6/16/2026
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
UpgradeNeutralOverweight$5.00 ➝ $9.00
6/10/2026
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
Set Price TargetBuy$6.50
6/10/2026
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
Initiated CoverageBuy$6.50
6/4/2026
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
Initiated CoverageBuy$6.00
5/22/2026
Codexis, Inc. stock logo
CDXS
Codexis
DowngradeSell (D-)Sell (E+)
5/22/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
Initiated CoverageOutperform$14.00
5/22/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
Initiated CoverageOutperform$14.00
5/21/2026
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
DowngradeSell (D-)Sell (E+)
5/18/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
Initiated CoverageOverweight
5/18/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
DowngradeStrong-BuyHold
(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
$3.50M62.39N/AN/A$1.02 per share4.12
Codexis, Inc. stock logo
CDXS
Codexis
$70.39M3.01N/AN/A$0.56 per share4.16
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$53.74M4.01$1.36 per share9.33$3.41 per share3.72
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$2.35M21.36N/AN/A$3.52 per share1.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
-$80.40M-$2.36N/AN/AN/A-2,193.72%-194.74%-95.64%N/A
Codexis, Inc. stock logo
CDXS
Codexis
-$43.97M-$0.37N/AN/AN/A-40.97%-68.09%-23.72%8/12/2026 (Estimated)
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$29.82M$2.664.74N/AN/AN/A149.23%34.50%8/5/2026 (Estimated)
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
-$24.83MN/AN/AN/AN/AN/AN/AN/AN/A

Latest RADX, CDXS, CAMP, and QTTB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
-$0.21-$0.32-$0.11-$0.32N/A$1.29 million
5/7/2026Q1 2026
Codexis, Inc. stock logo
CDXS
Codexis
-$0.11-$0.10+$0.01-$0.10$14.53 million$15.25 million
5/5/2026Q1 2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$0.68-$0.54+$0.14-$0.54$39.74 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
N/AN/AN/AN/AN/A
Codexis, Inc. stock logo
CDXS
Codexis
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
N/A
6.15
6.15
Codexis, Inc. stock logo
CDXS
Codexis
0.94
5.36
5.23
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
0.04
5.36
5.36
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
3.01
N/A

Institutional Ownership

CompanyInstitutional Ownership
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
N/A
Codexis, Inc. stock logo
CDXS
Codexis
78.54%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A

Insider Ownership

CompanyInsider Ownership
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
21.69%
Codexis, Inc. stock logo
CDXS
Codexis
3.50%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
34.46%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
64451.93 million40.66 millionNo Data
Codexis, Inc. stock logo
CDXS
Codexis
25090.90 million87.72 millionOptionable
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
3916.96 million11.11 millionN/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A11.81 millionN/AN/A

Recent News About These Companies

RADX: Fiscal 3Q:26 Cash Flow Report
Radiopharm Theranostics Ltd. ADR
Radiopharm Theranostics Reports Business Update
RADX: RAD 101 Phase IIb Interim Analysis

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CAMP4 Therapeutics stock logo

CAMP4 Therapeutics NASDAQ:CAMP

$4.20 -0.17 (-3.78%)
As of 03:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.

Codexis stock logo

Codexis NASDAQ:CDXS

$2.33 +0.07 (+3.10%)
As of 02:38 PM Eastern

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$12.70 -0.04 (-0.31%)
As of 03:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Radiopharm Theranostics stock logo

Radiopharm Theranostics NASDAQ:RADX

$4.25 +0.06 (+1.46%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.